ISPAD Guidelines 2018 - Chapter 21: Diabetes Technologies

Chapter 21:Diabetes Technologies

Jennifer L Sherr, Martin Tauschmann, Tadej Battelino, Martin de Bock, Gregory Forlenza, Rossana Roman, Korey Hood and David M Maahs


Since the turn of the century, diabetes care has entered a technological revolution.  While the advent of technologies to assist with diabetes management can be traced to the development of continuous subcutaneous insulin infusion pump therapy and home glucometers, with the development of more sophisticated devices, like continuous glucose monitors (CGM) and automated insulin delivery systems, integration of technology into clinical care has grown exponentially.  Furthermore, use of these technologies may provide more depth in how to achieve targeted control as compared to a singular hemoglobin A1c measurement.  CGM affords the opportunity to assess time spent in hypoglycemia (defined as sensor glucose <70mg/dL[3.9mmol/L]) as well as glycemic variability; thus, providing more clinically meaningful outcomes for new treatments in development as well as for day to day management of this chronic condition.  Thus, this new chapter of the ISPAD Consensus Guidelines, seeks to highlight diabetes technologies, an area of diabetes care that is rapidly evolving, by reviewing the evidence for their use and providing a practical approach on how to integrate these therapies into clinical care.

Contact Us

ISPAD Executive Office
c/o K.I.T. Group GmbH
Association & Conference Management
Kurfürstendamm 71
10709 Berlin, Germany










Join ISPAD

Click the link below to join the Society!


Join Today!










Phone: +49 (0)30 24603-210
Fax: +49 (0)30 24603-200
Email: secretariat@ispad.or
g










Privacy Policy
Terms of Service
Legal Notice    

Disclaimer



































 © 2018 International Society for Pediatric and Adolescent Diabetes (ISPAD)






Association Management Software Powered by YourMembership  ::  Legal